吲哚菁绿清除率与晚期慢性肝病关键疾病驱动机制生物标志物相关并预测慢加急性肝衰竭和死亡
ICG-R15与HVPG中度相关,对CSPH诊断准确性欠佳(AUROC 0.687),但与内皮功能障碍、系统性炎症等生物标志物相关,并独立预测失代偿肝硬化患者的ACLF/肝病相关死亡。
要点
- ICG-R15对CSPH诊断准确性欠佳,AUROC仅0.687。
- ICG-R15与MELD评分强相关,并与内皮功能障碍、炎症等标志物相关。
- ICG-R15独立预测失代偿肝硬化患者的ACLF/肝病相关死亡。
核心结论
- PDD测定的ICG-R15与ACLD关键疾病驱动机制相关,但对CSPH鉴别能力不足,可独立预测失代偿肝硬化患者的ACLF/肝病相关死亡。
主要发现
- cACLD患者中CSPH占62.4%,ICG-R15与HVPG中度相关(Spearman's rho 0.458;p < 0.001),诊断CSPH的AUROC为0.687(95% CI 0.585-0.789)。
- ICG-R15与MELD评分强相关(rho 0.701;p < 0.001),并与血管性血友病因子、C反应蛋白、降钙素原、白介素6及增强肝纤维化试验相关。
- 失代偿肝硬化中ICG-R15还与平均动脉压、血清钠和肾素水平相关。
- ICG-R15预测cACLD失代偿(SHR 1.042 [95% CI 1.008-1.077] 每%;p = 0.014)。
- ICG-R15独立预测失代偿肝硬化ACLF/肝病相关死亡(校正SHR 1.062 [95% CI 1.025-1.100] 每%;p < 0.001)。
临床怎么用
- ICG-R15不适用于CSPH的无创诊断,但可用于失代偿肝硬化患者的预后风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Indocyanine green (ICG) clearance, determined by venous sampling, has shown promising results in the diagnosis of clinically significant portal hypertension (CSPH) in compensated advanced chronic liver disease (cACLD) and prognostication in decompensated ACLD (decompensated cirrhosis). Data on ICG clearance measurement by pulse dye densitometry (PDD) via finger clip are comparatively scarce. AIMS: To evaluate the diagnostic (CSPH) and prognostic utility of ICG clearance throughout ACLD stages. METHODS: ACLD (liver stiffness ≥ 10 kPa) patients undergoing same-day hepatic venous pressure gradient (HVPG) measurement and ICG clearance assessment via PDD in 2017-2022 were recruited from the prospective Vienna Cirrhosis Study (VICIS, NCT03267615). RESULTS: Two hundred and sixty-one ACLD patients (cACLD: n = 115, decompensated cirrhosis: n = 146) were included. Among cACLD patients (CSPH: 62.4%), ICG retention 15 min (ICG-R15) correlated moderately with HVPG (Spearman's rho:0.458; p < 0.001) and yielded a suboptimal diagnostic accuracy for CSPH (AUROC: 0.687 [95% CI: 0.585-0.789]). ICG-R15 showed a strong correlation with the model for end-stage liver disease score (rho: 0.701; p < 0.001) and correlated with biomarkers of endothelial dysfunction (von Willebrand factor), systemic inflammation (C-reactive protein, procalcitonin, interleukin 6) and extracellular matrix remodelling (enhanced liver fibrosis test). In decompensated cirrhosis, ICG-R15 additionally correlated with mean arterial pressure, serum sodium and renin levels. ICG-R15 predicted decompensation (subdistribution hazard ratio [SHR]: 1.042 [95% CI: 1.008-1.077] per %; p = 0.014) in cACLD and independently predicted ACLF/liver-related mortality in decompensated cirrhosis (adjusted SHR: 1.062 [95% CI: 1.025-1.100] per %; p < 0.001). CONCLUSIONS: ICG-R15 by PDD correlates with portal hypertension and systemic inflammation/circulatory dysfunction as key disease-driving mechanisms in ACLD. While showing insufficient discrimination for CSPH, ICG-R15 independently predicted ACLF/liver-related mortality in decompensated cirrhosis.
引用
- Jachs M, Carvalho T, Simbrunner B, et al. Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease-Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute-on-Chronic Liver Failure and Death. Aliment Pharmacol Ther. 2025. PMID: 41194563. doi:10.1111/apt.70447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。